OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
April 18, 2023 07:30 ET
|
OpGen, Inc.
Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05, 2023 07:30 ET
|
OpGen, Inc.
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen,...
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
April 03, 2023 07:30 ET
|
OpGen, Inc.
PREPLEX project is part of broader InfectoGnostics Research Campus in Jena, GermanyTotal project volume of PREPLEX collaborative research is approximately $ 0.9 Mio ROCKVILLE, Md., April 03, 2023 ...
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023 14:25 ET
|
OpGen, Inc.
ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected...
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for 2022 was approximately $2.6 millionBalance sheet strengthened by recently closed public offering with gross proceeds of $7.5 millionConference call to be held March 29, 2023 at 4:30...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter...
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
March 01, 2023 07:30 ET
|
OpGen, Inc.
Approximately 5,000 sq. ft. facility houses laboratory and administrative operations under one location for future growth of businessARESdb, the company’s AMR knowledge database, has grown by 28% in...
OpGen Announces Exercise of All Prefunded Warrants
February 17, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Feb. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen subsidiary Ares Genetics announces granting of key patent in China
January 26, 2023 07:30 ET
|
OpGen, Inc.
Patent covers the identification and diagnostic use of genomic variants for the diagnosis of antibiotic resistant bacteriaThe China National Intellectual Property Administration (CNIPA) has granted...
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023 07:30 ET
|
OpGen, Inc.
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of December 31, 2022 was approximately $7.4 millionBalance sheet strengthened...